Related Experiment Video
Updated: Oct 13, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.7K
Mass Customized Outlook for Regenerative Heart Failure Care
Satsuki Yamada1,2, Jozef Bartunek3, Atta Behfar1,4
1Center for Regenerative Medicine, Marriott Family Comprehensive Cardiac Regenerative Medicine, Marriott Heart Disease Research Program, Van Cleve Cardiac Regenerative Medicine Program, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
International Journal of Molecular Sciences
|November 13, 2021
Summary
Novel cardiopoiesis protocols engineer stem cells for heart failure repair. These regenerative therapies show safety and efficacy, paving the way for affordable, mass-produced cardiac cell treatments.
Area of Science:
- Cardiovascular Biology
- Regenerative Medicine
- Stem Cell Therapy
Background:
- Heart failure pathobiology allows for reparative strategies.
- Regenerative therapies offer potential for organ repair but face challenges in cost and complexity.
- Novel cardio-regenerative approaches are needed for broader adoption.
Purpose of the Study:
- To develop and evaluate lineage-guided stem cell therapies for heart failure.
- To investigate the safety and efficacy of cardiopoietic cells in clinical trials.
- To streamline the manufacturing of cardiac repair-competent cells for affordability and scalability.
Main Methods:
- Molecular induction of the cardiopoiesis program in adult stem cells.
- Clinical trials using clinical-grade cardiopoietic cells in patients with ischemic heart failure.
- Development of a protein-free, mRNA-based protocol for cell engineering.
- Systems biology analysis of biobanked stem cells to deconvolve the secretome linked to therapeutic benefit.
Main Results:
- Cardiopoietic cells were safe and demonstrated therapeutic improvement in clinical trials.
- Treatment efficacy was observed within specific windows of treatment intensity and disease severity.
- A paracrine mode of action was identified through secretome analysis.
- Streamlined protocols enable affordable, mass-produced cardiac repair-competent cells.
Conclusions:
- Lineage-guided cardiopoiesis offers a viable strategy for heart failure regenerative therapy.
- Engineered cellular or cell-free platforms based on secretome knowledge represent next-generation therapeutics.
- Affordable, mass-produced biotherapeutics can advance equitable regenerative care for heart failure patients.
Related Concept Videos
01:30Heart Failure V: Medical Management
48
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
48
01:22Heart Failure VI: Adjunct Therapies
53
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
53
01:30Heart Failure VII: Nursing Interventions
183
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
183
01:28Mitral Regurgitation IV: Nursing Management
120
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
120
01:27Heart Failure I: Introduction
126
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
126
01:29Cardiomyopathy V: Interprofessional Care
64
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
64